{"id":19253,"date":"2022-10-11T15:48:35","date_gmt":"2022-10-11T10:18:35","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19253"},"modified":"2022-10-11T15:48:38","modified_gmt":"2022-10-11T10:18:38","slug":"pharma-news-for-merck-astrazeneca-gsk","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk","title":{"rendered":"Merck\u2019s Sotatercept Trial Result; PARP Rivals Closing in on AstraZeneca and Merck\u2019s Lynparza; FDA Clears GSK\u2019s Boostrix for Pertussis; Fast Track Designation to Nanoscope Therapeutics\u2019s MCO-010; FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab; Solid Biosciences to Acquire AavantiBio"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d26cf2c55d9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d26cf2c55d9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk\/#Mercks_Sotatercept_Clears_Phase_III_Trial\" >Merck\u2019s Sotatercept Clears Phase III Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk\/#PARP_Rivals_Closing_in_On_AstraZeneca_and_Mercks_Lynparza\" >PARP Rivals Closing in On AstraZeneca and Merck\u2019s Lynparza<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk\/#FDA_Awards_Fast_Track_Designation_to_Eftilagimod_Alpha_Plus_Pembrolizumab_in_Frontline_NSCLC\" >FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab in Frontline NSCLC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk\/#Solid_Biosciences_Announces_Acquisition_of_AavantiBio_and_Concurrent_USD_75_Million_Private_Placement\" >Solid Biosciences Announces Acquisition of AavantiBio and Concurrent USD 75 Million Private Placement<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk\/#FDA_Clears_GlaxoSmithKlines_Boostrix_Tdap_Vaccine_for_Pertussis\" >FDA Clears GlaxoSmithKline\u2019s Boostrix (Tdap) Vaccine for Pertussis&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk\/#FDA_Fast_Track_Designation_to_Nanoscope_Therapeuticss_MCO-010\" >FDA Fast Track Designation to Nanoscope Therapeutics\u2019s MCO-010<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-merck-s-sotatercept-clears-phase-iii-trial\"><span class=\"ez-toc-section\" id=\"Mercks_Sotatercept_Clears_Phase_III_Trial\"><\/span><strong>Merck\u2019s Sotatercept Clears Phase III Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Merck\u2019s USD 11.5 billion<\/strong> acquisition of <strong>Acceleron <\/strong>last year was based on the promise of pulmonary arterial hypertension (PAH) candidate <strong>sotatercept<\/strong>, which has recently met the mark in a much-anticipated phase III trial. The <strong>STELLAR trial<\/strong> found that adding the activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein to stable background therapy resulted in a significant increase in exercise capacity measured using the six-minute walking test in <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-epidemiology-forecast\">PAH patients<\/a>, meeting the trial\u2019s primary objectives.<\/p>\n\n\n\n<p>Furthermore, the drug met 8 of 9 secondary endpoints in the study, except for one that looked at the emotional and cognitive impact of PAH on patients, in what appears to be a resounding win for the program.<\/p>\n\n\n\n<p>\u201cIn the Phase III STELLAR study, sotatercept added to currently approved background therapy showed a profound effect on the primary efficacy outcome measure of improvement from baseline to 24 weeks in six-minute walk distance. The results from the secondary efficacy outcomes, including a favorable benefit seen in patients\u2019 time to a clinical-worsening event, are especially noteworthy,\u201d said <strong>Dr. Dean Y. Li, president of Merck Research Laboratories<\/strong>. \u201cWe believe that in totality, the results observed in the STELLAR study suggest that sotatercept has the potential to transform the treatment of patients with PAH. We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients.\u201d<\/p>\n\n\n\n<p>Merck expects sotatercept to generate multibillion-dollar sales, putting it at the center of a renewed push into <a href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-diseases\">cardiovascular disease therapies<\/a>. Merck is counting on Sotatercept to help it reduce its reliance on the <strong>USD 17 billion-a-year<\/strong> cancer immunotherapy blockbuster <strong>Keytruda (pembrolizumab)<\/strong>, which accounts for more than a third of its total sales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PARP_Rivals_Closing_in_On_AstraZeneca_and_Mercks_Lynparza\"><\/span><strong>PARP Rivals Closing in On AstraZeneca and Merck\u2019s Lynparza<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Since a few years ago, <strong>Lynparza<\/strong> from <strong>AstraZeneca <\/strong>and <strong>Merck &amp; Co.<\/strong> has been the undisputed market leader in the <strong>PARP inhibitor<\/strong> category. However, potential rivals are still eroding its market share. Two readouts for competitors from <strong>Clovis Oncology and Pfizer<\/strong> this week in prostate cancer\u2014one of several indications on the label for <a href=\"https:\/\/www.delveinsight.com\/report-store\/lynparza-api-insights\"><strong>Lynparza (olaparib)<\/strong><\/a>\u2014could spark a legal challenge to the <strong>USD 3 billion<\/strong> blockbuster drug.<\/p>\n\n\n\n<p>Pfizer reported that the anti-androgen therapy <a href=\"https:\/\/www.delveinsight.com\/report-store\/xtandi-drug-insight-and-market-forecast\"><strong>Xtandi (enzalutamide)<\/strong><\/a>, developed in collaboration with <strong>Astellas<\/strong>, and the <strong>PARP drug Talzenna (talazoparib)<\/strong>, in its <strong>phase III TALAPRO 2 trial<\/strong>, decreased radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy and whose condition is no longer responding to hormonal treatments.<\/p>\n\n\n\n<p>The combination decreased rPFS by <strong>20%<\/strong> when compared to <strong>Xtandi <\/strong>plus placebo, and there was a trend toward improved overall survival, which the researchers hope will statistically differ with a longer follow-up.&nbsp;<\/p>\n\n\n\n<p>After <strong>Xtandi<\/strong> or <strong>Pfizer\u2019s Zytiga (abiraterone)<\/strong> for mCRPC, <strong>AstraZeneca and Merck\u2019s<\/strong> medication was also approved in 2020, but only as a monotherapy for patients with tumors that express homologous recombination repair (HRR) gene mutations, such as BRCA1\/2 and ATM. <strong>Talzenna <\/strong>may become a treatment option for patients with or without HRR mutations if Pfizer successfully obtains FDA approval for <strong>TALAPRO 2<\/strong>, expanding the patient population for whom Lynparza is not currently indicated.<\/p>\n\n\n\n<p>Meanwhile, <strong>Clovis <\/strong>reported that its PARP medication <strong>Rubraca (rucaparib)<\/strong>, which had previously been used to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-resistant-prostate-cancer-mcrpc-market\">men with metastatic castration-resistant prostate cancer (mCRPC)<\/a> and taxane-based chemotherapy, had improved rPFS in <strong>phase III TRITON3 trial.<\/strong><\/p>\n\n\n\n<p><strong>TRITON3 <\/strong>will serve as the foundation for a new marketing application for the PARP inhibitor in mCRPC patients in an effort to broaden its uses. However, <strong>TRITON3\u2019s <\/strong>benefit was almost entirely restricted to the BRCA-positive population, with little effect on ATM, and Clovis has stated that it will now need to talk with the FDA about the final label.<\/p>\n\n\n\n<p>The new data was released not long after AstraZeneca and Merck decided to withdraw an FDA-accelerated approval for a late-line <a href=\"https:\/\/www.delveinsight.com\/report-store\/ovarian-cancer-market\">BRCA-mutated ovarian cancer treatment<\/a> because it did not prove effective in a confirmatory study. If approved, the partners\u2019 request to use Lynparza in the first-line setting for mCRPC, regardless of tumor mutations, will solidify the drug\u2019s advantage over competitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Awards_Fast_Track_Designation_to_Eftilagimod_Alpha_Plus_Pembrolizumab_in_Frontline_NSCLC\"><\/span><strong>FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab in Frontline NSCLC<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>FDA <\/strong>has granted a <strong>fast-track designation<\/strong> to <strong>eftilagimod alpha <\/strong>for use in combination with <strong>pembrolizumab <\/strong>as a frontline treatment for patients suffering with<strong> stage IIIB\/IV <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><strong>non\u2013small cell lung cancer<\/strong><\/a>.<\/p>\n\n\n\n<p>The designation was based on data from the <strong>phase II TACTI-002 trial<\/strong> that demonstrated the combination of <strong>efti <\/strong>and <strong>pembrolizumab <\/strong>obtained an <strong>overall response rate<\/strong> of <strong>38.6%<\/strong> by local read in the intent-to-treat population.<\/p>\n\n\n\n<p><strong>Efti<\/strong> is a first-in-class antigen-presenting cell activator for cancer treatment. Efti uses the unique features of <strong>LAG-3<\/strong> to activate innate and adaptive immunity through binding to APCs such as <strong>monocytes, dendritic cells<\/strong>, and <strong>macrophages via MHC II molecules<\/strong>. Antigens are presented to the adaptive immune system by activating <strong>APCs, anti-tumor cells expand<\/strong>, and <strong>CD4+<\/strong> and <strong>CD8+ T-cells<\/strong> are amplified.<\/p>\n\n\n\n<p>The <strong>TACTI-002<\/strong> trial assessed <strong>efti plus pembrolizumab<\/strong> as a first- or second-line treatment for patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><strong>NSCLC<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/head-and-neck-squamous-cell-carcinoma-market\"><strong>HNSCC<\/strong><\/a>.<\/p>\n\n\n\n<p>Patients in the first-line NSCLC cohort were required to have a histologically\/cytologically confirmed diagnosis of <strong>stage IIIB non-small cell lung cancer<\/strong> <strong>not amenable to curative treatment<\/strong> or <strong>stage IV NSCLC not amenable to EGFR\/ALK-based therapy<\/strong>.&nbsp;<\/p>\n\n\n\n<p>Key exclusion criteria for the first-line non-small cell lung cancer cohort included the ability for patients to receive curative intent treatment with either surgical-resection, chemo-radiation, and radiation; prior systemic therapy for stage IV disease unless the completion of treatment with chemotherapy and radiation as part of neoadjuvant\/adjuvant therapy occurred at least six months before the diagnosis of metastatic disease; the presence of an EGFR-sensitizing mutation or EML4\/ALK gene fusions; or the prior lung radiation therapy of more than 30 Gy within six months of the first dose of trial treatment.<\/p>\n\n\n\n<p>Enrolled patients received around <strong>30 mg<\/strong> of efti every two weeks for the first eight cycles, then every three weeks starting in cycle 9, plus 200 mg of pembrolizumab every three weeks. Each process lasted three weeks.<\/p>\n\n\n\n<p>The primary endpoint of the trial was overall response rate. Secondary endpoints consisted of <strong>time to response, duration of response, disease control rate, progression-free survival, overall survival, and safety.<\/strong><\/p>\n\n\n\n<p>Additional data showed that patients with a PD-L1 TPS of less than one experienced an overall response rate of<strong> 28.1%<\/strong>. Those with a PD-L1 TPS between <strong>1%<\/strong> and <strong>49% <\/strong>achieved an overall response rate of <strong>41.7%<\/strong>. Patients with a <strong>PD-L1 TPS <\/strong>of at least <strong>1%<\/strong> experienced an overall response rate of <strong>45.5%<\/strong>, and those with a <strong>PD-L1 TPS<\/strong> of at least<strong> 50%<\/strong> had an overall response rate of <strong>52.6%<\/strong>. Among all patients, the overall response rates for patients with squamous and non-squamous diseases were <strong>35%<\/strong> and <strong>38.9%<\/strong>, respectively.<\/p>\n\n\n\n<p>Further, <strong>8.6%<\/strong> of confirmed responders experienced disease progression within six months, and the median DOR has not yet been reached. The interim median PFS was around 7 months in the ITT, PD-L1 all-comers population. The temporary median PFS was <strong>8.4 months<\/strong> and <strong>11.8 months<\/strong> for patients with a PD-L1 TPS of at least <strong>1%<\/strong> and patients with a PD-L1 TPS of at least <strong>50%<\/strong>, respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Solid_Biosciences_Announces_Acquisition_of_AavantiBio_and_Concurrent_USD_75_Million_Private_Placement\"><\/span><strong>Solid Biosciences Announces Acquisition of AavantiBio and Concurrent USD 75 Million Private Placement<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Solid Biosciences<\/strong> and <strong>AavantiBio <\/strong>declared that the companies have entered into a conclusive merger agreement wherein Solid will acquire AavantiBio, including its pipeline assets and net cash. The companies will focus on advancing a portfolio of <strong>neuro-muscular<\/strong> and <strong>cardiac programs<\/strong> led by <strong>SGT-003<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\"><strong>Duchenne<\/strong><\/a>. Additional pipeline programs include <strong>AVB-202<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/friedreichs-ataxia-market\"><strong>Friedreich\u2019s ataxia<\/strong><\/a>, <strong>AVB-401<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/dilated-cardiomyopathy-market-forecast\"><strong>BAG3-mediated dilated cardiomyopathy<\/strong><\/a> and additional assets for the treatment of <strong>unrevealed cardiac diseases<\/strong>.&nbsp;<\/p>\n\n\n\n<p>Solid announced that it has signed a securities purchase agreement for a <strong>$75 million<\/strong> private placement with a limited group of accredited investors and institutional investors in support of the acquisition. The transaction is anticipated to close concurrently with the closing of the merger. The private placement is being led by existing investors such as <strong>Perceptive Advisors, Bain Capital Life Sciences<\/strong>, and <strong>RA Capital Management<\/strong>, and other new and existing investors are participating in the private placement, including <strong>Invus, CaaS Capital Management<\/strong>, <strong>Pura Vida Investments<\/strong>, and <strong>Laurion Capital Management<\/strong>.<\/p>\n\n\n\n<p>The combined company&#8217;s total cash and investments are anticipated to be roughly <strong>$215 million<\/strong> as soon as the merger and financing are completed. Solid anticipates that this will be enough to cover the combined company&#8217;s expected operating costs and capital expenditure needs by 2025 as well as enable the potential achievement of significant lead programs milestones. Subject to the usual closing requirements, the merger and private placement are anticipated to close in the fourth quarter of 2022.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Clears_GlaxoSmithKlines_Boostrix_Tdap_Vaccine_for_Pertussis\"><\/span><strong>FDA Clears GlaxoSmithKline\u2019s Boostrix (Tdap) Vaccine for Pertussis&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 10th October 2022, <strong>GSK plc (LSE\/NYSE: GSK)<\/strong> announced that the <strong>US FDA <\/strong>had approved its pertussis (whooping cough) therapy, <strong>BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed; Tdap).<\/strong> The therapy is intended for immunization during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age. BOOSTRIX has already been approved in over <strong>80 countries<\/strong> worldwide for treatment against different indications such as tetanus, diphtheria, and pertussis. With the recent approval from FDA, BOOSTRIX now becomes the first vaccine indicated in the US to protect infants younger than two months from pertussis (whooping cough).<\/p>\n\n\n\n<p>As per the statement issued by CDC, \u201cthe Tdap vaccination given during pregnancy provides the best protection to infants against whooping cough in the first months of life. Protective antibodies are passed from mother to child when pregnant women are vaccinated.\u201d Moreover, <strong>Roger Connor, President &#8211; Vaccines and Global Health, GSK,<\/strong> stated that \u201c<em>We\u2019re immensely proud to have the first-ever Tdap vaccine approved by the FDA specifically for this use during pregnancy. We believe this approval may help protect more infants from the potentially life-threatening implications of whooping cough<\/em>.\u201d<\/p>\n\n\n\n<p>Pertussis, also known as whooping cough, is violent and uncontrollable coughing. As per the CDC, since 2010, about <strong>15,000 to 48,000<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pertussis-epidemiology-forecast\"><strong>pertussis cases<\/strong><\/a> are being reported among people of all ages in the United States each year. Pertussis is a bacterial infection, it is being observed that infants are at high risk of complications from whooping cough as compared to other age groups because their immune systems are still developing. <a href=\"https:\/\/www.delveinsight.com\/report-store\/pertussis-pipeline-insight\"><strong>Pertussis treatment<\/strong><\/a> may be a bit tricky. Along with medication, they may need respiratory support and may require continuous observation. Antibiotics are a suggestive course of treatment. Even though they can take care of the infection, antibiotics cannot treat the cough itself. As per DelveInsight\u2019s assessment, globally, about 10+ key companies are actively working in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pertussis-market\"><strong>Pertussis treatment market<\/strong><\/a>. The launch of emerging therapies, including BOOSTRIX, is expected to improve the Pertussis treatment outcome immensely.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Fast_Track_Designation_to_Nanoscope_Therapeuticss_MCO-010\"><\/span><strong>FDA Fast Track Designation to Nanoscope Therapeutics\u2019s MCO-010<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On October 10, 2022, <strong>Nanoscope Therapeutics<\/strong> announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> had granted<strong> Fast Track Designation (FTD)<\/strong> to its <a href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-epidemiology-forecast\"><strong>Retinitis Pigmentosa (RP) therapy<\/strong><\/a>, <strong>MCO-010<\/strong>. Nanoscope\u2019s MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients with Retinitis Pigmentosa via intravitreal injection.<\/p>\n\n\n\n<p><strong>Sulagna Bhattacharya, CEO <\/strong>of<strong> Nanoscope<\/strong>, said, \u201cthe FDA&#8217;s decision to grant FTD underscores the importance of <strong>MCO-010<\/strong> to address a serious unmet need and validates its potential as an effective therapy for patients with Retinitis Pigmentosa.\u00a0The inputs from Nanoscope Therapeutics future state that they are looking forward to collaboratively interacting with the FDA to assess the next steps in the clinical development and future regulatory review of MCO-010.<\/p>\n\n\n\n<p>Earlier, In January 2022, 27 <a href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-market\"><strong>Retinitis Pigmentosa patients<\/strong><\/a> with advanced vision loss were enrolled in a multicenter, randomized, double-masked, sham-controlled <strong>RESTORE clinical trial (NCT04945772)<\/strong> of MCO-010. Further, top-line data from the clinical trial are expected in H1 2023. Further, in September of this year, enrollment was completed in <strong>Phase 2 open-label STARLIGHT clinical trial (NCT05417126)<\/strong> of <strong>MCO-010<\/strong> in patients with advanced vision loss due to Stargardt disease. Six-month data from the clinical trial are expected in H1 2023.<\/p>\n\n\n\n<p>As per DelveInsight, in 2021, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-market\"><strong>Retinitis Pigmentosa diagnosed prevalent population<\/strong><\/a> in 7MM was observed to be<strong> 259,003<\/strong>. The diagnosed prevalence of RP in the United States was found to be<strong> 111,994<\/strong>. Moreover, among the <strong>European 5 countries<\/strong>, <strong>Germany <\/strong>had the highest diagnosed prevalent population, followed by <strong>France<\/strong> and the <strong>United Kingdom<\/strong> in 2021. There is no known cure for Retinitis Pigmentosa. However, some treatment options are available in the market that can slow down the progression of Retinitis Pigmentosa. Owing to the ongoing therapeutics development activities and the approval and launch of emerging therapies such as MCO-010, among others, is expected to improve the Retinitis Pigmentosa treatment outlook in the coming immensely.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck\u2019s Sotatercept Clears Phase III Trial Merck\u2019s USD 11.5 billion acquisition of Acceleron last year was based on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has recently met the mark in a much-anticipated phase III trial. The STELLAR trial found that adding the activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein to stable [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":19256,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[143,349,420,979,1111,3742,18932,18925,18926,639,5789,11777,19814],"industry":[17225],"therapeutic_areas":[17231,17228,17244],"class_list":["post-19253","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cardiovascular-disease","tag-latest-pharma-news","tag-news","tag-non-small-cell-lung-cancer-nsclc","tag-nsclc","tag-ovarian-cancer-treatment","tag-pertussis","tag-pertussis-treatment","tag-pertussis-vaccine","tag-pharma-news","tag-recent-pharma-news","tag-retinitis-pigmentosa","tag-retinitis-pigmentosa-treatment","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Merck, AstraZeneca, GSK, Solid Biosciences, Immutep<\/title>\n<meta name=\"description\" content=\"Merck\u2019s Sotatercept; AZ and Merck\u2019s Lynparza; GSK\u2019s Boostrix for Pertussis; Nanoscope&#039;s MCO-010; Eftilagimod Alpha Plus Pembrolizumab\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Merck, AstraZeneca, GSK, Solid Biosciences, Immutep\" \/>\n<meta property=\"og:description\" content=\"Merck\u2019s Sotatercept; AZ and Merck\u2019s Lynparza; GSK\u2019s Boostrix for Pertussis; Nanoscope&#039;s MCO-010; Eftilagimod Alpha Plus Pembrolizumab\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-11T10:18:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-11T10:18:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/11154544\/Pharma-News-Merck-AstraZeneca-and-GSK-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Merck, AstraZeneca, GSK, Solid Biosciences, Immutep","description":"Merck\u2019s Sotatercept; AZ and Merck\u2019s Lynparza; GSK\u2019s Boostrix for Pertussis; Nanoscope's MCO-010; Eftilagimod Alpha Plus Pembrolizumab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Merck, AstraZeneca, GSK, Solid Biosciences, Immutep","og_description":"Merck\u2019s Sotatercept; AZ and Merck\u2019s Lynparza; GSK\u2019s Boostrix for Pertussis; Nanoscope's MCO-010; Eftilagimod Alpha Plus Pembrolizumab","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-10-11T10:18:35+00:00","article_modified_time":"2022-10-11T10:18:38+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/11154544\/Pharma-News-Merck-AstraZeneca-and-GSK-1.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk","name":"Pharma News | Merck, AstraZeneca, GSK, Solid Biosciences, Immutep","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/11154544\/Pharma-News-Merck-AstraZeneca-and-GSK-1.png","datePublished":"2022-10-11T10:18:35+00:00","dateModified":"2022-10-11T10:18:38+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Merck\u2019s Sotatercept; AZ and Merck\u2019s Lynparza; GSK\u2019s Boostrix for Pertussis; Nanoscope's MCO-010; Eftilagimod Alpha Plus Pembrolizumab","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-merck-astrazeneca-gsk#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/11154544\/Pharma-News-Merck-AstraZeneca-and-GSK-1.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/11154544\/Pharma-News-Merck-AstraZeneca-and-GSK-1.png","width":772,"height":482,"caption":"Pharma News Merck, AstraZeneca, and GSK"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/11154544\/Pharma-News-Merck-AstraZeneca-and-GSK-1-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cardiovascular disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ovarian Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pertussis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pertussis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pertussis vaccine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cardiovascular disease<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">Ovarian Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Pertussis<\/span>","<span class=\"advgb-post-tax-term\">pertussis treatment<\/span>","<span class=\"advgb-post-tax-term\">pertussis vaccine<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Oct 11, 2022","modified":"Updated on Oct 11, 2022"},"absolute_dates_time":{"created":"Posted on Oct 11, 2022 3:48 pm","modified":"Updated on Oct 11, 2022 3:48 pm"},"featured_img_caption":"Pharma News Merck, AstraZeneca, and GSK","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19253"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19253\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19256"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19253"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19253"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}